Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer

PURPOSE: Androgen deprivation therapy may increase diabetes risk. As the benefits of primary androgen deprivation therapy for localized prostate cancer are controversial, and most prostate cancer survivors are of advanced age with comorbidities, it is important to determine if primary androgen depri...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Urol
Egile Nagusiak: Tsai, Huei-Ting, Keating, Nancy L., Van Den Eeden, Stephen K., Haque, Reina, Cassidy-Bushrow, Andrea E., Yood, Marianne Ulcickas, Smith, Matthew R., Potosky, Arnold L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4543371/
https://ncbi.nlm.nih.gov/pubmed/25524243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2014.12.027
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak